Acumen Pharmaceuticals, Inc.
ABOSHealthcare|Biotechnology|US
$0.22
+0.01 (+4.54%)
DCF Value
$0.38
Tangible Book / Share
$0.48
Cash / Share
$1.09
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06335173 A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | Alzheimer Disease | P2 | Active | 542 | RCT, Double-blind | sabirnetug, Placebo |
| NCT06511570 A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants | Alzheimer Disease | P1 | Completed | 28 | Open-label | sabirnetug (ACU193) |
| NCT04931459 A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD | Alzheimer Disease | P1 | Completed | 65 | RCT, Double-blind | ACU193, Placebo |